Wie können wir helfen?
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
You do not have access to this post.
1445534
{:IMKF9J8M}
1
https://www.zotero.org/styles/urban-research-and-practice?source=1
50
default
1
1
153
http://www.hautkrebs-leitlinien.de/wp-content/plugins/zotpress/